135 related articles for article (PubMed ID: 37210287)
1. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome.
Logothetis CJ; Hahn AW
Eur Urol; 2024 Jan; 85(1):3-7. PubMed ID: 37210287
[TBL] [Abstract][Full Text] [Related]
2. Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
Wassersug RJ; Schellhammer PF; Wibowo E
Eur Urol; 2024 Jun; 85(6):e173-e174. PubMed ID: 38538424
[No Abstract] [Full Text] [Related]
3. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis.
Ryan S; Jenkins MA; Win AK
Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):437-49. PubMed ID: 24425144
[TBL] [Abstract][Full Text] [Related]
4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
[TBL] [Abstract][Full Text] [Related]
6. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.
Davidsson S; Fiorentino M; Andrén O; Fang F; Mucci LA; Varenhorst E; Fall K; Rider JR
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2280-7. PubMed ID: 21953116
[TBL] [Abstract][Full Text] [Related]
7. Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.
Campi R; Brookman-May SD; Subiela Henríquez JD; Akdoğan B; Brausi M; Klatte T; Langenhuijsen JF; Linares-Espinos E; Marszalek M; Roupret M; Stief CG; Volpe A; Minervini A; Rodriguez-Faba O
Eur Urol Focus; 2019 Nov; 5(6):1029-1057. PubMed ID: 29661588
[TBL] [Abstract][Full Text] [Related]
8. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
[TBL] [Abstract][Full Text] [Related]
9. Testosterone and prostate cancer: challenging dogma with data.
Spark RF
Endocr Pract; 2008 Oct; 14(7):902-3. PubMed ID: 18996822
[No Abstract] [Full Text] [Related]
10. Prostate cancer--biology of metastasis and its clinical implications.
Dong JT; Rinker-Schaeffer CW; Ichikawa T; Barrett JC; Isaacs JT
World J Urol; 1996; 14(3):182-9. PubMed ID: 8806197
[TBL] [Abstract][Full Text] [Related]
11. Fostering shared decision-making about prostate cancer screening among African American men patients and their primary care providers: a randomized behavioral clinical trial.
Echeverri M; Felder K; Anderson D; Apantaku E; Leung P; Hoff C; Dennar P
Trials; 2022 Aug; 23(1):653. PubMed ID: 35964061
[TBL] [Abstract][Full Text] [Related]
12. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer.
Ma C; Wang Y; Wilson KM; Mucci LA; Stampfer MJ; Pollak M; Penney KL
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35047751
[TBL] [Abstract][Full Text] [Related]
13. Vaccines as monotherapy and in combination therapy for prostate cancer.
Rotow J; Gameiro SR; Madan RA; Gulley JL; Schlom J; Hodge JW
Clin Transl Sci; 2010 Jun; 3(3):116-22. PubMed ID: 20590682
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
15. The metabolic syndrome is associated with reduced risk of prostate cancer.
Tande AJ; Platz EA; Folsom AR
Am J Epidemiol; 2006 Dec; 164(11):1094-102. PubMed ID: 16968859
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus.
Grönberg H; Isaacs SD; Smith JR; Carpten JD; Bova GS; Freije D; Xu J; Meyers DA; Collins FS; Trent JM; Walsh PC; Isaacs WB
JAMA; 1997 Oct; 278(15):1251-5. PubMed ID: 9333266
[TBL] [Abstract][Full Text] [Related]
17. MRI of the prostate.
Rifkin MD
Crit Rev Diagn Imaging; 1990; 31(2):223-62. PubMed ID: 2288663
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers.
Makarov DV; Feuer Z; Ciprut S; Lopez NM; Fagerlin A; Shedlin M; Gold HT; Li H; Lynch G; Warren R; Ubel P; Ravenell JE
Trials; 2021 Feb; 22(1):128. PubMed ID: 33568208
[TBL] [Abstract][Full Text] [Related]
19. Choline intake and risk of lethal prostate cancer: incidence and survival.
Richman EL; Kenfield SA; Stampfer MJ; Giovannucci EL; Zeisel SH; Willett WC; Chan JM
Am J Clin Nutr; 2012 Oct; 96(4):855-63. PubMed ID: 22952174
[TBL] [Abstract][Full Text] [Related]
20. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
